SAREPTA THERAPEUTICS INC. - COMMON STOCK

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28 Feb 2022 17:17:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

22 Feb 2022 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases

01 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2022 17:15:13 By Nasdaq GlobeNewswire

Sarepta Therapeutics’ Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy

10 Jan 2022 09:50:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 07:32:34 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Dec 2021 19:45:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 Nov 2021 17:16:56 By Nasdaq GlobeNewswire

Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and Development

17 Nov 2021 07:31:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Appoints Stephen L. Mayo, Ph.D., to its Board of Directors

17 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

03 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Present at Upcoming Investor Conferences

02 Nov 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 Oct 2021 17:15:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021

27 Oct 2021 07:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock

13 Oct 2021 20:15:04 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021

12 Oct 2021 15:04:09 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock

12 Oct 2021 15:01:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne

11 Oct 2021 08:13:02 By Nasdaq GlobeNewswire

Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio

04 Oct 2021 15:30:00 By Nasdaq GlobeNewswire

Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

04 Oct 2021 06:00:00 By Nasdaq GlobeNewswire